Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) entered into the equity transfer agreement to acquire 36.3636% stake in OHMK (Tianjin) Medical Technology Co., Ltd. from Tianjin Huacan Enterprise Management Consulting Partnership, Shanghai Ermei Enterprise Management Consulting Partnership, Yuan Yibing, Lian Songyong and Chen Guangfei for approximately CNY 150 million on July 31, 2023. Currently, Shanghai Haohai holds 63.6364% in OHMK. As part of the transaction, Shanghai Haohai will acquire 6.6% stake from Yuan Yibing, 11.88% stake from Chen Guangfei, 7.92% stake from Lian Songyong, 6.3636% stake from Shanghai Ermei Enterprise Management Consulting Partnership and 3.6% stake from Tianjin Huacan Enterprise Management Consulting Partnership, post the transfer OHMK (Tianjin) Medical Technology Co., Ltd. will become a wholly owned subsidiary of Shanghai Haohai Biological Technology Co., Ltd. The consideration will be funded by internal resources of the Shanghai Haohai.

The unaudited consolidated profit after tax of OHMK for the six months ended June 30, 2023 is CNY 0.04 million. The transaction is conditional on approval of the Acquisition by the registered limited partners of Shanghai Ermei and Tianjin Huacan and the approval of the acquisition by the board of Shanghai Haohai. The completion will be the date on which Shanghai Haohai pays 70% of the consideration, with the remaining consideration to be paid within the next 3 months.